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Abstract 
Neutropenic enteritis (NE) or enterocolitis (NEC) is a rare, but potentially 
life-threatening side effect of neutropenia-inducing chemotherapy agents. 
Generally, its occurrence is attributed to leukaemia-associated 
chemotherapies. Two cases of NE have been reported after the appliance 
of pemetrexed for treatment of non-small cell lung cancers. To our 
knowledge, NE has never been reported due to treatment with pemetrexed 
for malignant pleural mesothelioma (MPM). We present a case of MPM in a 
77-year-old male suffering from severe NE one week after the seventeenth 
cycle of pemetrexed in the course of maintenance therapy for MPM, which 
could be treated successfully with antibiotic coverage and supportive 
measures. Concomitantly the patient showed a severe hyperpigmentation 
of his entire integument sparing the palms of both hands and the soles of 
his feet. After exclusion of alternative causes of skin hyperpigmentation, a 
pemetrexed-induced cutaneous hyperpigmentation was assumed 
according to two previous case reports. A combination of both pemetrexed-
induced side effects in one patient has not been reported to date.  
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Introduction 
Malignant mesothelioma is a highly malignant neoplasm related to 
asbestos-exposure, which develops from transformed cells originating in 
the mesothelium. The most common anatomical site of its manifestation is 
the pleura (malignant pleural mesothelioma, MPM), peritoneum, 
pericardium, or tunica vaginalis. Pemetrexed is an antifolate agent 
approved in 2004 for first-line chemotherapy of malignant mesothelioma in 
combination with carboplatin [1]. Furthermore, it has been approved as 
single-substance therapy for second line treatment of mesothelioma [2]. 
Several studies have shown a better safety profile and less gastrointestinal 
side effects of pemetrexed compared to other regimes in the treatment of 
non-small cell lung cancer (NSCLC) [3]. However, two cases of severe 
neutropenic enterocolitis (NEC) have been reported after the treatment with 
pemetrexed during treatment of NSCLC [4,5]. The incidence of NEC is 
unknown, but its occurrence is mainly attributed to neutropenia-inducing 
chemotherapies for acute leukaemias with a reported incidence of around 
5% [6].  
Here, we present the first case of a severe neutropenic enteritis (NE) in a 
patient receiving pemetrexed for maintenance therapy against MPM, who 
concomitantly showed a remarkable, diffuse cutaneous hyperpigmentation, 
which was previously reported in two cases only in association with 
pemetrexed [7,8].    
 
Case Report 
A 77–year-old, never smoking, Caucasian man (height 179 cm, weight 71 
kg, body surface area 1.89 m2) with stage III MPM (cT3, N0, M0) was 
admitted to the emergency department because of severe, diffuse 
abdominal pain with normal bowel movements, weight loss, and mild fever 
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beginning one week after the seventeenth administration of pemetrexed in 
the course of maintenance chemotherapy. The dose given was slightly 
reduced to about 420 mg/m2, since the kidney function was moderately 
impaired at that time (glomerular filtration rate 49 ml/min, serum creatinine 
122 µmol/l, serum urea 8.9 mmol/l). The diagnosis of MPM was confirmed 
23 months previous to the current presentation. The patient was initially 
treated with three cycles of a first-line chemotherapy including carboplatin 
(225 mg/m2) and pemetrexed (500 mg/m2) every four weeks. Thereafter, he 
was found in partial remission, and maintenance single-substance therapy 
with pemetrexed was introduced leading to stabilization of tumor growth.  
His further past medical history revealed coronary artery bypass graft 
surgery 10 years, and mitral valve repair 6 months prior to the event. 
Moreover, he suffered from intermittent atrial fibrillation and stage II chronic 
kidney failure. Medication on admission was phenprocoumon, 
acetylsalicylate, amiodarone, ramipril, torasemide, esomeprazole, 
potassium chloride, folic acid and cholecalciferol. Because of his recent 
abdominal pain, the patient additionally took paracetamol and 
butylscopolamine. 
  
At presentation, the patient was normotensive and normocardic. The body 
temperature was 37.1° Celsius. The patient’s entire integument showed 
severe, diffuse hyperpigmentation sparing only the palms of his hands and 
the soles of his feet. The auscultation of heart, lungs and the abdomen was 
unrevealing. The abdomen was soft, but diffusely tender to percussion and 
palpation. Laboratory studies were only remarkable for moderate anaemia 
(haemoglobin 83 g/l) and elevated inflammatory markers (C-reactive 
protein 53 mg/l, erythrocytes sedimentation rate 100 mm/h), but leukocytes 
within the normal range  
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A contrast enhanced computed tomography (CT) scan of the abdomen 
revealed segmental small bowel wall thickening (5 mm) without 
involvement of colon or caecum precluding ileus, bowel perforation, 
ischemia, (pseudomembranous or inflammatory) colitis, acute appendicitis, 
cholecystitis, or pancreatitis (figure 1) . Moreover, radiologic signs of 
peritoneal mesothelioma manifestation were not present. An empirical 
antibiotic therapy with metronidazole was initiated, because infectious 
enteritis was assumed, though there was no fever, no diarrhea and a 
normal white blood count. Three days after, the patient developed febrile 
neutropenia with a minimal neutrophiles count of 220/l, fever up to 38.6°C 
and worsened abdominal pain and new onset diarrhea. Thrombocytes 
decreased to 109000/l, and haemoglobin was unchanged. 
Although there was no microbiologic evidence of an infection in the 
previously taken blood and stool specimen (including negative stool antigen 
testing for Clostridium difficile and negative serum cytomegalovirus PCR), 
the anti-infective treatment was expanded with piperacillin/tazobactam and 
fluconazole assuming neutropenic enteritis in order to prevent penetrating 
peritonitis. Moreover, bowel rest and total parenteral nutrition was initiated. 
The following week, the patient’s condition and his neutrophiles count 
(4630/l) improved considerably. A follow-up abdominal CT scan confirmed 
resolution of the bowel wall thickening. After a total of 43 days, the patient 
was transferred to a rehabilitative institution. The asymptomatic but severe 
hyperpigmentation of his entire skin was unchanged during hospitalization. 
The patient’s former Caucasian complexion had been started to turn a dark 
brownish shade (figure 2-3) two months previous to the current 
presentation without being exposed to sun light or using self-tanning 
lotions. Haemochromatosis seemed unlikely, as ferritin and transferrin 
saturation were within normal ranges one year before. Moreover, adequate 
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increase of cortisol levels upon cosyntropin and a normal morning serum 
cortisol level excluded adrenal insufficiency. Also, other less frequent 
differential diagnoses of diffuse cutaneous hyperpigmentation could have 
been excluded by absent exposition to silver containing agents precluding 
systemic argyria. Considering pharmacological side effects due to his usual 
medications, only pemetrexed and amiodarone was a potential causative 
agent for dermal hyperpigmentation. However, amiodarone was introduced 
after the first observation of the patient’s color-related skin alterations.  
 
Discussion 
The pathogenesis of NE (or accordingly neutropenic enterocolitis, NEC) is 
poorly understood. The disease seems to be caused by the combined 
effect of chemotherapy-induced neutropenia and direct toxicity of 
chemotherapeutical agents against the intestinal mucosa [9]. Together with 
endotoxin-production, this mechanism enables intestinal bacteria to invade 
the bowel wall leading to ischemia, ulceration and necrosis [4]. This 
potentially life-threatening disorder is commonly seen following induction 
chemotherapy for leukaemia. Furthermore, it is occasionally observed after 
highly aggressive chemotherapies against solid tumors [5]. Two cases of 
NE or NEC have been reported after the appliance of pemetrexed in the 
treatment of NSCLC [4,10]. To date, only one case of fatal NEC has been 
reported after chemotherapy for MPM [11]. However the latter case 
occurred administering a chemotherapy agent other than pemetrexed. Our 
patient suffered from combination of severe NE and diffuse cutaneous 
hyperpigmentation during maintenance chemotherapy with pemetrexed, 
although his glomerular filtration rate was more than the lower limit of 45 
ml/min, and, however, the given dose had been reduced to 723 mg/m2. 
Current treatment recommendations for MPM do not include maintenance 
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therapy [12]. But pemetrexed was shown to be safe and generally well 
tolerated [4]. The pemetrexed-associated colitis rate was 0.6% in the 
clinical trial database, and gastrointestinal side effects are reported to be 
less than 1% [3,4]. Two months previous to the patient’s presentation, he 
noticed a progressive hyperpigmentation of his entire integument sparing 
the palms of both hands and the soles of his feet. He denied any sun 
exposure or the use of self-tanning lotions, and alternative differential 
diagnoses of cutaneous hyperpigmentation including haemochromatosis, 
adrenal insufficiency, and systemic argyria had been excluded. According 
to two previous case reports, a pemetrexed-induced cutaneous 
hyperpigmentation was therefore assumed [7,8]. The reported patients 
developed hyperpigmentation shortly after administration of pemetrexed. In 
the first case, the patient showed asymptomatic hyperpigmentation of his 
palms and soles after the second cycle of pemetrexed [7]. The second 
report describes two patients, who developed diffuse hyperpigmentation of 
the upper part of the body resolving after cessation of pemetrexed [8]. But, 
the dose and number of pemetrexed administrations are not mentioned in 
these patients. Anyway, cutaneous adverse effects are supposed to 
correlate directly with the administered dose and number of pemetrexed 
cycles, respectively [13], Thus, the prolonged appliance of pemetrexed 
could play a causative role in the development of hyperpigmentation [8], but 
also in the pathogenesis of NE(C), irrespective of glomerular filtration rate 
as seen in the present case. The pathogenesis of pemetrexed-induced 
hyperpigmentation of the skin yet remains unclear. Anyway, pemetrexed is 
associated with several cutaneous side effects described elsewhere [8].  
 
Conclusion 
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The increasing use of pemetrexed and other neutropenia inducing 
chemotherapies, and the thereby achieved improved survival rates are 
likely to cause higher rates of severe or potentially life-threatening adverse 
effects. Abdominal pain and bowel wall thickening in CT scans in patients 
being treated with pemetrexed should be an alarm signal for clinicians to 
consider possible NE(C). Aggressive and multidisciplinary approach should 
be initiated rapidly to prevent fatal outcomes [14]. To date, pemetrexed-
induced cutaneous hyperpigmentation may be underestimated. However, 
both side effects should be considered after exclusion of alternative 
causes, particularly when pemetrexed is administered for a prolonged 
period of time, even in adequate dosage adapted to the current kidney 
function. 
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